Considering the seriousness of the condition, the good benefit-risk profile of MAVIRET®, the alternatives available, the place of MAVIRET® in the therapeutic strategy, and the likely impact of MAVIRET® on public health, the committee considered the actual benefit of MAVIRET® to be ‘important’ in the indication of the Marketing Authorisation, proposing a reimbursement rate of 100%. The 50 mg / 20 mg presentations of the drug were considered to provide no improvement in actual benefit (ASMR V) compared to the presentations already listed.